Laboratory test abnormal – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Laboratory test abnormal – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Dapagliflozin for Heart and Kidney Health in Adults After ICU Discharge with Heart or Kidney Issues https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-heart-and-kidney-health-in-adults-after-icu-discharge-with-heart-or-kidney-issues/ Wed, 29 Apr 2026 15:03:51 +0000 https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-heart-and-kidney-health-in-adults-after-icu-discharge-with-heart-or-kidney-issues/ This clinical trial is focused on patients who have been discharged from the Intensive Care Unit (ICU) and are experiencing certain heart and kidney issues. Specifically, it involves adult patients who have a decreased estimated glomerular filtration rate (eGFR), which is a measure of kidney function, and/or have had an acute kidney injury (AKI) during their ICU stay, and/or have elevated levels of a heart-related protein called NT-proBNP at the time of discharge. The study aims to evaluate the effects of a medication called dapagliflozin, which is marketed under the name Forxiga, on heart and kidney health one year after ICU discharge.

Participants in the study will be randomly assigned to receive either Forxiga or a placebo, which looks like the medication but does not contain the active ingredient. The purpose of the study is to assess whether Forxiga can improve outcomes related to heart and kidney health, such as reducing the risk of heart failure, preventing a significant decline in kidney function, and improving overall survival rates one year after leaving the ICU. The study will be conducted over a period of one year, during which participants will be monitored for any changes in their health status.

The trial will also track any hospitalizations due to heart or kidney issues, as well as any serious side effects that may occur. This includes monitoring for conditions like severe chronic kidney disease, new episodes of acute kidney injury, and other cardiovascular events. Safety will be a key focus, with attention given to potential side effects such as urinary tract infections, diabetic ketoacidosis, and major hypoglycemia. The study aims to provide valuable information on the potential benefits of Forxiga for patients recovering from serious health conditions after an ICU stay.

]]>